

August 7, 2018

Personal Matters / Ex. 6

Email: Personal Email / Ex. 6

Mr. Andrew Wheeler
Acting Administrator
United States Environmental Protection Agency
Mail Stop 1101A
1200 Pennsylvania Ave. NW
Washington, DC 20460

OFFICE OF THE
MEDICAL SECRETARY

2018 AUG 10 AM 10:28

RECEIVED

Dear Acting Administrator Wheeler,

As a retired EPA toxicologist formerly associated with the Office of Pesticide Programs (OPP), I know first hand the frustrations of having to deal with epidemiological reports from the open literature.

I believe that Mr. Pruitt's directive regarding transparency in regulatory decisions especially related to epidemiological studies has merit. With this communication, I hope to provide a path forward that will produce a document that clearly indicates that the EPA conducted a thorough critical review of epidemiological studies occurring in the open literature or otherwise. The resulting document will clearly articulate the basis for its decision to allow the use of such publications to impact the risk assessment or determine that the study does not provide sufficient proof for its conclusions.

First of all, there is a great discrepancy in the review of the toxicology studies that industry is required to submit in order to register their chemical products. These studies follow strict protocol guidelines and are conducted under stringent good laboratory practices (GLP), quality assurance (QA) and animal ethics reviews as well as rigid reporting standards. These studies in the OPP have multiple layers of primary and secondary review most often by contractors at a very significant expenditure of taxpayer funds and program resources. The studies are essentially transcribed into Data Evaluation Records (DERs) that have to state what was done and what the results were since the reviewers cannot misrepresent what the study reported. The reviewers, however, can indicate study deficiencies and identify responses not already indicated by the report. The reviewers responsible for the reviews are clearly identified and responsible for their decisions.

In marked contrast, epidemiological studies appearing in the open literature (or otherwise) follow a mixed bag of study designs, GLP, QA, ethics and reporting practices. However, these studies are most often accepted at their face value without evidence of a critical review or identification of the responsible individuals.

This practice is unfair to the public. Studies used for risk assessment should have the same level of critical review no matter what their source is.

A current example is how the OPP handled chlorpyrifos that I have personal experience with. The most recent SAP review indicated problems with the original Columbia epidemiological study that should have been resolved long before several previous expensive SAP meetings were held. There are no similar DER reviews indicating the responsible reviewers provided to support the OPP's actions or attempts to use the study endpoints for risk assessment that I know of.

With the concept of a disparity in the degree of review of animal studies conducted to support the registration of a pesticide (or other chemical) and the acceptance of epidemiological studies on their face value, I am proposing that:

An Epidemiological Study Peer Review Council be established with the goal of creating a transparent document reflecting a thorough review of the study be established by EPA.

The details of this Council are in the attached document entitled **"Proposal for the Review of Epidemiology Studies from the Open Literature (or otherwise) Being Considered for a Basis for Regulatory Action: Establishment of Agency Wide Epidemiology Study Peer Review Council (ESPRC) and the resulting product Record of Epidemiology Study Review (ROESR)."**

The resulting product should provide a transparent assessment and whether or not an epidemiology study can be used for risk assessment. The responsible individuals are identified and would defend their decisions from objections from either industry or public interest groups.

I certainly hope that you will find this proposal helpful and forward it to the appropriate individuals concerned with evaluation of toxicity and risk assessment. If there are questions concerning how this Council could be implemented, please contact me. I will be happy to make a presentation on how this Council can contribute to the goal of making transparent decisions for risk assessment. Electronic copies of the proposal can be provided on request from EPA staff.

Thank you for giving this suggestion your consideration.

John D. Doherty, Ph.D.
(DABT 1982-2017)
Independent Toxicologist

Email: Personal Email / Ex. 6

PS. This proposal was presented at the afternoon session of the open meeting on Transparency held on July 17, 2018.

Doherty Epidemiological Study Council Proposal

August 7, 2018

Subject: Proposal for the Review of Epidemiology Studies from the Open Literature (or otherwise) Being Considered for a Basis for Regulatory Action: Establishment of Agency Wide Epidemiology Study Peer Review Council (ESPRC) and the resulting product Record of Epidemiology Study Review (ROESR).

To: Mr. Andrew Wheeler
Acting Administrator
Environmental Protection Agency
Mail Code 1101A
1200 Pennsylvania Ave NW
Washington, DC 20460

From: John D. Doherty, Ph.D.
(DABT: 1982-2017)

Email: Personal Email / Ex. 6



As a retired toxicologist in the EPA's Office of Pesticide Programs, I believe that there is merit to Mr. Pruitt's directive that only studies where the public can review the supporting data can be used for regulatory decisions. Epidemiological studies should not be accepted based on their face value without critical evaluation of all aspects of the study. I also recognize that such supporting data may not be available because of various reasons including the confidentiality of the subjects in the study cohort.

There should be a middle ground where the Agency determines that the study can be used for regulatory decisions when all supporting data are not available. The decision to use the study in the absence of an independent review of the original data should *not be* the responsibility of one individual. The following is a proposal to justify the use of an epidemiological study when not all of the supporting data are available. Or to otherwise state clearly why the study cannot be used without the submission of additional data.

A Call for the Standardization of the Review of an Epidemiology Studies – Establishment of an Agency wide Epidemiology Study Peer Review Council (ESPRC) and the product Record of Epidemiological Study Review (ROESR).

Each epidemiology study occurring in the open literature or otherwise needs to have a supporting formal **Record of Epidemiological Study Review (ROESR)** that clearly delineates the justification for a decision to include or not include the study in the regulatory decisions for the chemical or environmental situation. The production of the ROESR will consist of the separate and independent reports of several Sub-Committees that will be integrated by the **Epidemiological Study Peer Review Council (ESPRC)** and signed by the Council Chairperson and each Council member.

Doherty Epidemiological Study Council Proposal

August 7, 2018

It is important to have *independent* Sub-discipline committees review the study so that the biases of other sub-disciplines are minimized. The Sub-committee members should be drawn from the relevant staff throughout the Agency as well as other government agencies as needed. Each member of the Sub-committees will sign their respective Sub-committee reports.

The roles of the six suggested Sub-Committees and Council Chairperson are as follows:

1. ***Ethics Evaluation Sub-Committee.*** This sub-committee will evaluate all aspects of the ethical treatment of the individuals in the cohorts. This includes that it will identify how additional data can be provided to the Agency in a manner that will assure the identities of the individuals are protected.

2. ***Endpoint Evaluation Sub-Committee:*** This evaluation would limit its conclusions with regard to how well the character of the endpoint itself was assessed for and whether or not the effect reported is plausibly related to treatment or within normal variation. The latter includes how many subjects in a cohort are needed to make a meaningful statistical difference for the particular lesion in question.

This Sub-committee will provide commentary on the consistency of characterization of the endpoint, resolution of confounds as well as any known other chemicals or conditions that affect the normal distribution of the endpoint.

The experts in this Sub-committee will vary depending upon the endpoint claimed by the epidemiological study and consist of experts in cancer, behavioral response, or other appropriate discipline for interpretation of the significance of the endpoint.

3. ***Exposure Assessment Sub-Committee:*** The role of the exposure assessment Sub-committee is limited to determining that the methodology and reliability used to determine the exposure of the cohort is adequate and appropriate. The Sub-committee would provide commentary on whether or not exposure was supported by analytical chemical data, by oral history or otherwise. Also, if the actual persons exposed provided oral history by direct conversation, survey or by telephone. The committee will determine if indirect exposure information was provided by a relative (or friend or coworker) is reliable.

4. ***Statistical Evaluation Sub-Committee:*** In the initial review of the study, the sole role of the statistical evaluation sub-committee is limited to determining if the statistical methods were/were not appropriate and adequately conducted to support the conclusion of the report. This committee would not redo the statistics at this time since the original data would be needed. Input from Sub-committees 1 (ethics), 2 (3ndpoint evaluation) and 3 (exposure assessment) that clarifies all

August 7, 2018

issues that are the responsibility of their respective disciplines would be needed before statistical reanalysis could be conducted. Thus, receipt of the original data in a manner that satisfies Sub-committees 1, 2 and 3 and well as any requests by the Statistical Evaluation Sub-committee before any statistical reanalysis would be conducted.

5. Analytical Chemistry Assessment Sub-Committee: The role of the analytical chemistry committee is limited to determining if the analytical techniques/ methodology were appropriate and adequate for the study. In some cases where no analytical chemistry data were generated, the committee will comment on the need to have included such data and/or if quantitative analysis of exposure data was even possible.

6. Animal Toxicity and Structure Activity Relationship (SAR) Assessment Sub-Committee: In most cases with chemicals, the Agency should already have a battery of standard animal toxicity studies that were required for the registration of that chemical. There may also be studies in the open literature attempting to define the toxicity of the chemical. Thus, the person(s) responsible for evaluating the animal toxicity studies would be a member of this Sub-committee. In addition, this Sub-committee will have individuals that can address the SAR issues in relation to the possibility that the chemical could affect the endpoint in question.

It should be noted here that a Record of Review (ROR) signed by at least two qualified toxicologist is needed for any publication supporting a mechanism of action for the chemical.

If the endpoint occurs in animals or has SAR correlates, such information can support the epidemiological findings. If not, it does not automatically dismiss the epidemiological findings since the effect on the endpoint may be unique to humans.

7. Council Chairperson, Council meetings and resulting product: ROESR:

The **Council Chairperson** should not be in the same program that has responsibility for regulating the chemical or environmental condition. That is, if the chemical is a pesticide, the Chairperson cannot be from the Office of Pesticide Programs (OPP). Representatives of OPP may still be on the Council if an epidemiological study with a pesticide is being reviewed.

At the initial **Council meeting**, the Council will discuss the conclusions of each the six Sub-committees. In some cases, the Council may determine that the association between exposure and the endpoint is otherwise strong enough to support regulatory action to protect the public health and no additional information is needed from the study authors.

Doherty Epidemiological Study Council Proposal

August 7, 2018

During the initial meeting the Council can overrule a request for additional data made by any of the Sub-Committees. However, clear justification for overruling a Sub-Committee's decisions must be provided.

In other cases, the Council may determine that there is a definite need to require additional data supporting the study methodologies and conclusions are required. The Council would then notify the authors articulating of the need for the specific additional information.

The Council will also determine if the authors of the epidemiological report should be requested to attend a closed meeting with the Council and Sub-committee members. The purpose of the meeting will be an opportunity for the study authors to address any concerns that the Sub-committees have. This will include problems with providing any additional information that the Sub-committees requested. If the study authors refuse to attend a requested meeting, the Council will determine if the study should be rejected outright.

The Council Chairperson (or secretary of the Council) will prepare the **ROESR** product that contains the decision with supporting justification. The ROESR product would include the report of the Council with the Chairperson and Council members' signatures. Separate attachments for the *signed* Sub-Committee reports and the original epidemiological report (i.e. a publication) will also be attached. An executive summary of any meeting(s) with the study authors will also be appended.

Purpose:

The purpose of this procedure is to assure that responsible persons for each of the critical Sub-disciplines *independently* reviewed the study in terms of their expertise. The resulting ROESR that either determines that the study can be used in the absence of additional original data or the need for critical additional data is determined will be clearly indicated.

The Council Chairperson and members of the Council and the sub-discipline committees own their decisions and are responsible for defending them.

If industry or any concerned public interest groups object to the conclusions, they can address the conclusions presented in the ROESR and/or the sub-disciplines.

Therefore the decisions in the resulting ROESR should be transparent. The current system renders too much power to individuals that are sometimes not clearly identified who can profit by making career projects for themselves based on the face value of the publication.

Doherty Epidemiological Study Council Proposal

August 7, 2018

I am well aware that an epidemiological publication (or otherwise) in the open literature is going to be controversial. However, preparing a ROESR for such studies with the several sub-disciplines all independently contributing to the Agency's determination of the conclusions in the report should greatly help to minimize controversies.

The ROESR is not a final conclusion (no documents in EPA should be considered final). It is very likely that a Science Advisory Panel will ultimately review the ROESR. Also, as new information is generated, the ROESR can be updated and the recommendations for use (or otherwise) can be adjusted as appropriate.

Personal Matters / Ex. 6


André Gide

equivalent

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200
 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400
 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500
 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600
 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700
 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800
 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900
 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000
 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 103

2560732.100002519107

CERTIFIED MAIL



2560 4322 7734 0957
1000 0231 9102

Andrew Wheeler
EPA Administrator
41547 Environmental Protection Agency

AUG 10 2018

RETURN REQUEST
RECEIVED

300 Pennsylvania Ave. N.W.
Washington, D.C. 20460

15

ED_002389_00028917-00008